Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monette

Showing results (711-720 of 740) with videos related to

Pageof 74
Sort By:
Blood Advances|June 17, 2026
Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphomaZijun Y Xu-Monette, Chang Wang, Dehong Wu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 8, 2015
Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapyZhiyu Liu, Zijun Y Xu-Monette, Xin Cao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2014
Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countriesChi Young Ok, Ling Li, Zijun Y Xu-Monette, et al.
Science Translational Medicine|August 28, 2015
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivoLaura R Saunders, Alexander J Bankovich, Wade C Anderson, et al.
Leukemia|August 30, 2016
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphomaY Xia, Z Y Xu-Monette, A Tzankov, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 7, 2015
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOPZijun Y Xu-Monette, Bouthaina S Dabaja, Xiaoxiao Wang, et al.
Infection Control and Hospital Epidemiology|January 30, 2025
Real-world clinical impact of plasma cell-free DNA metagenomic next-generation sequencing assayIshminder Kaur, Bennett Shaw, Ashrit Multani, et al.
Cancer Immunology Research|February 13, 2019
Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCLZiju Y Xu-Monette, Min Xiao, Qingyan Au, et al.
Blood|August 29, 2013
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium ProgramZijun Y Xu-Monette, Michael B Møller, Alexander Tzankov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2016
Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell LymphomaZijun Y Xu-Monette, Qipan Deng, Ganiraju C Manyam, et al.
Pageof 74

Showing results (711-720 of 740) with videos related to

Sort By:
Pageof 74
Blood Advances|June 17, 2026
Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphomaZijun Y Xu-Monette, Chang Wang, Dehong Wu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 8, 2015
Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapyZhiyu Liu, Zijun Y Xu-Monette, Xin Cao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2014
Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countriesChi Young Ok, Ling Li, Zijun Y Xu-Monette, et al.
Science Translational Medicine|August 28, 2015
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivoLaura R Saunders, Alexander J Bankovich, Wade C Anderson, et al.
Leukemia|August 30, 2016
Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphomaY Xia, Z Y Xu-Monette, A Tzankov, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 7, 2015
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOPZijun Y Xu-Monette, Bouthaina S Dabaja, Xiaoxiao Wang, et al.
Infection Control and Hospital Epidemiology|January 30, 2025
Real-world clinical impact of plasma cell-free DNA metagenomic next-generation sequencing assayIshminder Kaur, Bennett Shaw, Ashrit Multani, et al.
Cancer Immunology Research|February 13, 2019
Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCLZiju Y Xu-Monette, Min Xiao, Qingyan Au, et al.
Blood|August 29, 2013
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium ProgramZijun Y Xu-Monette, Michael B Møller, Alexander Tzankov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2016
Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell LymphomaZijun Y Xu-Monette, Qipan Deng, Ganiraju C Manyam, et al.
Pageof 74